Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis

Phase

N/A

Condition

Common Cold

Allergy

Allergies & Asthma

Treatment

N/A

Clinical Study ID

NCT05708157

GCIRB2022-327

Ages > 19
All Genders

Study Summary

Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale [VAS] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid for 2 weeks. After 2-week treatment, changes in clinical parameters including VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be evaluated.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Perinnial allergic rhinitis diagnosed by a doctor
Positive for one or more of inhalant perinneal allergen in skin prick test or serumspecific IgE measurement
Age: 19 years or older
Allergic rhinitis symptoms not controlled (VAS ≥5) by 2-week treatment with intranasalcorticosteroid

Exclusion

Exclusion Criteria:

Compliance for one or more drugs in last 2 weeks: <80%
Use of oral corticosteroid, oral or intranasal decongestant in last 2 weeks
Initiation of allergen-specific immunotherapy in last 12 months
Seasonal allergic rhinitis
Chronic rhinosinusitis other than allergic rhinitis
Nasal polyposis
Comorbid diseases including infectious, respiratory, cardiologic, renal,gastrointestinal, endocrinologic, oncologic, hemotologic and immunologic disorderswhich investigators judge to affect on the study significantly.
Patients' rejection
Pregenancy or lactation

Study Design

January 17, 2023

February 29, 2024

Study Description

Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale [VAS] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid. In addition to VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be measured before treatment (baseline) and 2 week after treatment. The differences between parameters before treatment and those after 2-week treatment will be statistically analyzed using paired student t test, and p<0.05 was considered statistically significant.

Connect with a study center

Gachon University Gil Medical Center
Incheon, 21565
Korea, Republic of
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.